SCHEMBL3140601

SCHEMBL3140601

CC(C)(C)c1ccc(-c2ccc(OCC3Cn4ccc(=O)nc4O3)cc2)cc1

nearest known ligand 0.94

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 12/20 0.94
ALDH1A1 P00352 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KMT2A Q03164 3/20 0.39
TP53 P04637 2/20 0.39
MAPT P10636 2/20 0.39
HPGD P15428 2/20 0.39
TSHR P16473 2/20 0.39
MEN1 O00255 2/20 0.39
CYP1A2 P05177 1/20 0.39
PPARG P37231 1/20 0.39
HIF1A Q16665 1/20 0.39
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3140586 1.00 GRM2 (0.94) GRM2ALDH1A1CYP3A4CYP2C19SMN1; SMN2
SCHEMBL3134410 0.97 GRM2 (1.00) GRM2ALDH1A1CYP3A4CYP2C19SMN1; SMN2
SCHEMBL3134401 0.97 GRM2 (1.00) GRM2ALDH1A1CYP3A4CYP2C19SMN1; SMN2
SCHEMBL3140070 0.97 GRM2 (1.00) GRM2ALDH1A1CYP3A4CYP2C19SMN1; SMN2
SCHEMBL3140146 0.94 GRM2 (0.94) GRM2ALDH1A1CYP3A4CYP2C19SMN1; SMN2
SCHEMBL3140136 0.94 GRM2 (0.94) GRM2ALDH1A1CYP3A4CYP2C19SMN1; SMN2
SCHEMBL1513575 0.90 GRM2 (0.76) GRM2ALDH1A1CYP3A4CYP2C19SMN1; SMN2
SCHEMBL1513577 0.90 GRM2 (0.76) GRM2ALDH1A1CYP3A4CYP2C19SMN1; SMN2
SCHEMBL3144388 0.88 GRM2 (0.72) GRM2SMN1; SMN2NPSR1KMT2AMAPT
SCHEMBL3144375 0.88 GRM2 (0.72) GRM2SMN1; SMN2NPSR1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642603-B2 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof SANOFI (FR) 2014-02-04 US claimed
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2010-03-25 US claimed
EP-2137193-B1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI SA (FR) 2017-08-09 EP disclosed
US-8642603-B2 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof SANOFI (FR) 2014-02-04 US disclosed
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF GRM2, GRM1, GRIN2C GRM2 1/4885ALDH1A1 1875/4885CYP3A4 1201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.